Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, January 2012, Pages: 74

Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Graft Versus Host Disease (GVHD) Therapeutics market. The report identifies the key trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Graft Versus Host Disease (GVHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Graft Versus Host Disease (GVHD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graft Versus Host Disease (GVHD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Graft Versus Host Disease (GVHD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Graft Versus Host Disease (GVHD) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Graft Versus Host Disease (GVHD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Graft Versus Host Disease (GVHD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Graft Versus Host Disease (GVHD) Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Overview
2.1.1 Classification of GVHD
2.2 Epidemiology
2.3 Etiology
2.4 Signs and Symptoms
2.4.1 Acute GVHD
2.4.2 Chronic GVHD
2.5 Diagnosis
2.5.1 Laboratory Tests
2.5.2 Imaging Tests
2.5.3 Biopsies
2.5.4 Other Tests and Procedures
2.6 Prophylaxis
2.7 Treatment
2.7.1 Primary or First-Line Therapy for aGVHD
2.7.2 Secondary or Second-Line Therapy for aGVHD
2.7.3 Primary or First-Line Therapy for cGVHD
2.7.4 Secondary or Second-Line Therapy for cGVHD
2.7.5 Supportive Care
2.8 GlobalData Pipeline Report Guidance
3 GVHD Therapeutics - Market Characterization
3.1 Major Markets, Market Size (2005-2010)
3.2 Major Markets, Market Forecast (2010-2018)
3.3 US Market Size (2005-2010)
3.4 The US Market Forecast (2010-2018)
3.5 The UK Market Size (2005-2010)
3.6 The UK Market Forecast (2010-2018)
3.7 Germany Market Size (2005-2010)
3.8 Germany Market Forecast (2010-2018)
3.9 Italy Market Size (2005-2010)
3.10 Italy Market Forecast (2010-2018)
3.11 France Market Size (2005-2010)
3.12 France Market Forecast (2010-2018)
3.13 Spain Market Size (2005-2010)
3.14 Spain Market Forecast (2010-2018)
3.15 Japan Market Size (2005-2010)
3.16 Japan Market Forecast (2010-2018)
3.17 Drivers and Barriers for GVHD Therapeutic Market
3.17.1 Drivers for GVHD Market
3.17.2 Barriers for GVHD Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 GVHD Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 GVHD Market Marketed Products Profile
4.2.1 Corticosteroids
4.2.2 Cyclosporine
4.2.3 Antithymocyte Globulin (ATG) (equine/rabbit)
4.2.4 Mycophenolate Mofetil (MMF)
4.2.5 Tacrolimus
4.3 Key Takeaway
5 GVHD - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 GVHD Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 GVHD Therapeutics - Phase III Clinical Pipeline
5.3.2 GVHD Therapeutics - Phase II Clinical Pipeline
5.3.3 GVHD Therapeutics - Phase I/II Clinical Pipeline
5.3.4 GVHD Therapeutics - Phase I Clinical Pipeline
5.3.5 GVHD Therapeutics - Preclinical Pipeline
5.4 GVHD Pipeline by Mechanism of Action
5.5 GVHD Technology Trends Analytical Framework
5.6 GVHD Therapeutics - Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 ATIR (ANX-530)
5.7.2 Budesonide
5.7.3 Leukotac (inolimomab)
5.7.4 OrBec (Beclomethasone Dipropionate, Oral BDP, Oral Beclomethasone Dipropionate)
5.7.5 Prochymal
5.8 Key Takeaway
6 GVHD Therapeutics - Clinical Trials Mapping
6.1 Overview
6.2 Clinical Trials Mapping by Region/Country
6.3 Clinical Trials Mapping by Phase
6.4 Clinical Trials Mapping by Trial Status
6.5 Clinical Trials Mapping by Overall Sponsors
6.6 Clinical Trials Mapping by Prominent Sponsors
6.7 Participants in Therapeutic Clinical Trials - Companies
7 GVHD Therapeutics - Implications for Future Competition
7.1 Future Market Competition Scenario
8 Global GVHD Therapeutics - Future Players
8.1 Introduction
8.2 Dr. Falk Pharma GmbH
8.2.1 Company Overview
8.3 EUSA Pharma, Inc.
8.3.1 Company Overview
8.4 Kiadis Pharma B.V.
8.4.1 Company Overview
8.5 Osiris Therapeutics, Inc.
8.5.1 Company Overview
8.5.2 Business Overview
8.6 Soligenix, Inc.
8.6.1 Company Overview
8.6.2 Business Overview
9 Licensing and Partnership Deals
10 Global Graft Versus Host Disease Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources

1.1 List of Tables
Table 1: Clinical Staging and Grading of aGVHD
Table 2: Clinicopathologic Classification of cGVHD
Table 3: Incidence of GVHD, 2010
Table 4: Signs and Symptoms of aGVHD and cGVHD
Table 5: GVHD Therapeutics, Global, Market Revenue ($m), 2005-2010
Table 6: GVHD Therapeutics, Global, Revenue Forecasts ($m), 2010-2018
Table 7: GVHD Therapeutics, The US, Market Historical Revenue ($m), 2005-2010
Table 8: GVHD Therapeutics, The US, Historical Revenue Forecasts ($m), 2010-2018
Table 9: GVHD Therapeutics, The UK, Market Historical Revenue ($m), 2005-2010
Table 10: GVHD Therapeutics, The UK, Revenue Forecasts ($m), 2010-2018
Table 11: GVHD Therapeutics, Germany, Market Revenue ($m), 2005-2010
Table 12: GVHD Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
Table 13: GVHD Therapeutics, Italy, Market Revenue ($m), 2005-2010
Table 14: GVHD Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
Table 15: GVHD Therapeutics, France, Market Revenue ($m), 2005-2010
Table 16: GVHD Therapeutics, France, Revenue Forecasts ($m), 2010-2018
Table 17: GVHD Therapeutics, Spain, Market Revenue ($m), 2005-2010
Table 18: GVHD Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
Table 19: GVHD Therapeutics, Japan, Market Revenue ($m), 2005-2010
Table 20: GVHD Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018
Table 21: GVHD Therapeutics - Phase III Clinical Pipeline, 2011
Table 22: GVHD Therapeutics - Phase II Clinical Pipeline, 2011
Table 23: GVHD Therapeutics - Phase I/II Clinical Pipeline, 2011
Table 24: GVHD Therapeutics - Phase I Clinical Pipeline, 2011
Table 25: GVHD Therapeutics - Preclinical Pipeline, 2011
Table 26: Mechanism of Action Constituting Classes in Figure 28
Table 27: GVHD Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 28: GVHD Clinical Trials by Region – Number, 2011
Table 29: GVHD Clinical Trials by Phase, 2011
Table 30: GVHD Clinical Trials by Status, 2011
Table 31: GVHD Clinical Trials by Overall Sponsors, 2011
Table 32: GVHD Clinical Trials by Prominent Sponsors, 2011
Table 33: GVHD Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
Table 34: Dr. Falk Pharma GmbH- GVHD Therapeutics Pipeline
Table 35: EUSA Pharma, Inc. - GVHD Therapeutics Pipeline
Table 36: Kiadis Pharma B.V. - GVHD Therapeutics Pipeline
Table 37: Osiris Therapeutics, Inc.- GVHD Therapeutics Pipeline
Table 38: Soligenix, Inc. - GVHD Therapeutics Pipeline
Table 39: GVHD Therapeutics, Licensing and Partnership Deals

1.2 List of Figures
Figure 1: Stages of GVHD after Allogeneic HCT
Figure 2: Mechanisms of Injury by Tissue-Infiltrating Alloreactive T-Cells
Figure 3: Skin Affected by GVHD (Stage 3)
Figure 4: Oral Mucosal Changes in Patients with cGVHD
Figure 5: GVHD Therapeutics, Global, Market Revenue ($m), 2005-2010
Figure 6: GVHD Therapeutics, Market Share ($m, %), 2010
Figure 7: GVHD Therapeutics, Global, Revenue Forecasts ($m), 2010-2018
Figure 8: GVHD Therapeutics, Forecast Market Share ($m, %), 2018
Figure 9: GVHD Therapeutics, The US, Market Revenue ($m), 2005-2010
Figure 10: GVHD Therapeutics, The US, Revenue Forecasts ($m), 2010-2018
Figure 11: GVHD Therapeutics, The UK, Market Revenue ($m), 2005-2010
Figure 12: GVHD Therapeutics, The UK, Revenue Forecasts ($m), 2010-2018
Figure 13: GVHD Therapeutics, Germany, Market Revenue ($m), 2005-2010
Figure 14: GVHD Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
Figure 15: GVHD Therapeutics, Italy, Market Revenue ($m), 2005-2010
Figure 16: GVHD Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
Figure 17: GVHD Therapeutics, France, Market Revenue ($m), 2005-2010
Figure 18: GVHD Therapeutics, France, Revenue Forecasts ($m), 2010-2018
Figure 19: GVHD Therapeutics, Spain, Market Revenue ($m), 2005-2010
Figure 20: GVHD Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
Figure 21: GVHD Therapeutics, Japan, Market Revenue ($m), 2005-2010
Figure 22: GVHD Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018
Figure 23: GVHD Therapeutic Market - Drivers and Barriers
Figure 24: Opportunity and Unmet Need in the GVHD Therapeutic Market
Figure 25: Strategic Competitor Assessment of Marketed Products for GVHD, 2010
Figure 26: Pipeline Products by Phase of Clinical Development, 2011
Figure 27: GVHD Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 28: GVHD Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 29: Technology Trends Analytical Framework of GVHD Pipeline, 2011
Figure 30: Technology Trends Analytical Framework of GVHD Pipeline - Description, 2011
Figure 31: GVHD Clinical Trials by Region, 2011
Figure 32: GVHD Clinical Trials by Phase, 2011
Figure 33: GVHD Clinical Trials by Status, 2011
Figure 34: GVHD Clinical Trials by Sponsors, 2011
Figure 35: GVHD Clinical Trials by Prominent Sponsors, 2011
Figure 36: GVHD Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
Figure 37: Implications for Future Market Competition in the GVHD Market, 2011
Figure 38: GVHD Therapeutics, Clinical Pipeline by Company, 2011
Figure 39: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Graft Versus Host Disease (GVHD) Therapeutics market. The report identifies the key trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Graft Versus Host Disease (GVHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The GVHD Therapeutics Market is Forecast to Show Moderate Growth until 2018

GlobalData estimates that the global Graft Versus Host Disease (GVHD) therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018. This moderate growth is primarily attributed to the strong pipeline landscape, increase in the number of Hematopoietic Stem Cell Transplants (HSCTs) and the launch of new first-in-class drugs with improved safety and efficacy profiles.

Unmet Need Continues to Challenge the Pipeline Drugs

GlobalData analysis shows that the current market landscape is weak as generic immunosuppressive agents are used off-label. These products have moderate levels of efficacy and safety and as a result, GVHD remains a major cause of mortality following HSCT. The current market has significant unmet need and thus provides significant potential for pipeline drugs that are stronger in terms of efficacy and safety. However, considering the fact that a majority of the pipeline products are first-in-class but are Mesenchymal Stem Cell (MSC) therapies aimed primarily at the prevention of GVHD, the therapeutic market will continue to remain dominated by the existing drugs. If approved, these new therapies will create a new market.

Increased Use of HSCTs for Hematologic Malignancies

HSCT is a treatment option for certain types of leukemia and lymphoma such as Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS) when chemotherapy and/or radiation therapy fail. The past two decades have seen a gradual increase in the number of allogeneic HSCTs performed annually. The increasing incidence of leukemia has led to more elderly patients receiving reduced-intensity or non-myeloablative transplants because the risk of ALL, ALL and MDS increases in people above the age of 50 years. GVHD risk also increases with age, meaning that incidence is increasing and the market is growing.

Dr. Falk Pharma GmbH
EUSA Pharma, Inc.
Kiadis Pharma B.V.
Osiris Therapeutics, Inc.
Soligenix, Inc.

Customers who bought this item also bought

• Global Migraine Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• Global Schizophrenia Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Intranasal Drug Delivery - Global Business Strategic Report
• Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• RNA Interference (RNAi) - Global Strategic Business Report
• Herpes Simplex Virus Treatment - Global Strategic Business Report
• Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline
• CNS Therapeutics - Global Strategic Business Report
• Regenerative Medicine - Global Strategic Business Report